MediWound Ltd. business relationships
Companies named in MediWound Ltd.’s 20-F filed 2026-03-05, and public companies whose annual reports name MediWound Ltd.. Each link shows the sentence it came from. Scores are Engagemii’s AI visibility scores.
- AEO visibility
- 5.4 / 10
- AI naming
- 72 / 100 Top 1% in its category
- Agent readiness
- 25 / 100
- AI adoption
- 0 / 100
Named in MediWound Ltd.’s annual report 5
“In December 2020, Teva Pharmaceutical Industries Ltd ("TEVA") has agreed to revise a settlement agreement from March 2019, which was comprised of past agreement for collaboration in the development, manufacturing and commercialization of solutions for the burn and chronic wound care markets, as well...” SEC filing
“was responsible for discovery projects in the ubiquitin system, conducted in collaboration with GlaxoSmithKline plc and Teva.” SEC filing
“License Agreement, dated as of May 6, 2019, by and between the Registrant and Vericel Corporation(15)” SEC filing
“commercial partner in the U.S., Vericel Corporation ("Vericel"), was unable to release NexoBrid into the commercial channel” SEC filing
“In the United States, the Company entered into an exclusive license and supply agreement with Vericel Corporation ("Vericel") to commercialize Nexobrid in North America.” SEC filing
Companies whose annual reports name MediWound Ltd. 2
“Through the parties' License Agreement, MediWound has licensed to us a family of patents covering NexoBrid.” SEC filing
“We rely on MediWound for the manufacture, production, and supply of NexoBrid, and our business, financial condition, and results of operations could be materially adversely affected to the extent the manufacture, production, and supply of NexoBrid is disrupted or delayed.” SEC filing
Links are read automatically from SEC annual reports (10-K, 20-F, 40-F). In a hand check of random links, about 8 in 10 were real business relationships, so every link carries its source sentence.